Comparative Pharmacology
Head-to-head clinical analysis: ADVIL LIQUI GELS versus EC NAPROSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL LIQUI GELS versus EC NAPROSYN.
ADVIL LIQUI-GELS vs EC-NAPROSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
200–400 mg orally every 4–6 hours as needed; maximum 1200 mg/day.
500-1000 mg orally twice daily; maximum 1500 mg/day.
None Documented
None Documented
1.8 to 2.5 hours. The short half-life supports dosing every 4 to 6 hours for acute pain and fever.
Terminal elimination half-life 12-17 hours (mean 14 hours); prolonged in elderly and renal impairment
Renal excretion of metabolites and conjugates accounts for approximately 90% of an administered dose. Less than 1% is excreted unchanged. Biliary/fecal elimination accounts for about 10%.
Renal (95%) as unchanged drug (10%) and conjugated metabolites (60%) and other metabolites (25%); biliary/fecal (5%)
Category C
Category C
NSAID
NSAID